Evidence map›Paper›PMID 34268792›Full record

ArticleJournal of clinical laboratory analysis2021

Aberrant expression of five miRNAs in papillary thyroid carcinomas.

De-Hui Qiao, Xue-Mei He, Xian Deng, Yi-Chi Ji, Hui Yang, Lian Cheng, Xiang-Yu Zhou

Abstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. MicroRNA Profiling in Papillary Thyroid Cancer.International journal of molecular sciences · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Aberrant expression of five miRNAs in papillary thyroid carcinomas.Journal of clinical laboratory analysis · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

De-Hui QiaoDepartment of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, China.ORCID https://orcid.org/0000-0001-8128-273X
Xue-Mei HeDepartment of Central Laboratory, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Xian DengDepartment of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Yi-Chi JiDepartment of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Hui YangDepartment of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Lian ChengDepartment of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Xiang-Yu ZhouDepartment of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, China.ORCID https://orcid.org/0000-0001-8976-9489

Funding

Luzhou-SWMU supported the screening and functional analysis of molecular markers for thyroid cancer based on GWAS; China; 2017LZXNYD-Z01
6 · The paper itself

Abstract

backgroundThe miRNAs play critical roles in the progression of various tumors. Our study aimed to screen and identify miRNAs to investigate their diagnostic and prognostic value for papillary thyroid carcinoma (PTC).

methodsmiRNAs were evaluated in PTC (n = 30) tissues, A-PTC (n = 30), benign nodules (n = 35) and A-benign nodules (n = 35). The expression levels of five miRNAs were quantified using real-time, quantitative PCR. ROC analysis was used to evaluate the miRNA diagnostic value.

resultsThe expression of miR-1296-5p, miR-1301-3p, and miR-532-5p was significantly downregulated (p = 0.0001, p = 0.0006, p = 0.0024, respectively), while miR-551b-3p and miR-455-3p were significantly upregulated in PTC tissues compared to A-PTC tissues (p = 0.0005, p = 0.0046, respectively). Interestingly, the expression of miR-1296-5p was downregulated, while miR-551b-3p and miR-455-3p were upregulated in the A-PTC group compared to the A-benign group. Moreover, the miR-1296-5p expression level was associated with tumor size, the number of foci and the TNM stage; the miR-455-3p expression level was correlated with patient age, tumor size, and TNM stage; and the miR-532-5p expression level was correlated with patient age, lymph node metastasis and TNM stage correspondingly. ROC analysis revealed that the AUCs for miR-1301-3p, miR-1296-5p, miR-455-3p, miR-532-5p, and miR-551b-3p were 0.773, 0.790, 0.783, 0.744, and 0.650, respectively.

conclusionsOur results indicated that miR-1296-5p, miR-1301-3p, miR-532-5p, miR-551b-3p, and miR-455-3p are aberrantly expressed in papillary thyroid carcinomas and correlated with clinicopathological features. ROC curve analysis indicated that these five miRNAs have a potential diagnostic value. Consequently, we speculate that the five altered miRNAs may serve as potential diagnostic and prognostic biomarkers for PTC.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedPrognosisROC CurveThyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorMicroRNAsMIRN-1296 microRNA, humanMIRN1301 microRNA, humanMIRN455 microRNA, humanMIRN532 microRNA, humanMIRN-551 microRNA, humanclinicopathological featuresdiagnosismiRNAmolecular markerpapillary thyroid carcinoma

Identifiers

PMID34268792
PMCPMC8418488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.